Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label dose-escalation study of IMC-M113V in virologically suppressed chronic HIV infection
2024-513938-38-00Phase 2Authorised
- Sponsor
- Immunocore
- Start
- Apr 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of amtabafusp alfa in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Immunocore. Primary endpoint: Safety and tolerability. Planned start Apr 2022; status: authorised.
02
Drugs
amtabafusp alfa
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-513938-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513938-38-00.